腺病毒介导OX40Ig基因转移在诱导大鼠肝脏移植物长期存活中的作用和机制研究
|
摘要
目的
(1)改良二袖套法大鼠原位肝脏移植动物模型的成功建立。
(2)改良二袖套法大鼠原位肝脏移植急性排斥动物模型的建立。
(3)重组腺病毒pAdeasy-1-pAdTrack-CMV-OX40Ig(AdOX40Ig)的构建
(4)研究重组腺病毒AdOX40Ig不同感染剂量对人肝细胞HL-7702生长的影响及其感染效率,筛选最佳感染剂量进行该重组腺病毒的生物学功能研究。
(5)探讨腺病毒介导OX40Ig基因转移在诱导大鼠肝脏移植物长期存活中的作用和机制。
方法
(1)通过改良的双袖套法对130对SD大鼠进行了原位肝移植。前面40对为预试验组,中间60对为实验熟练组,后面30对为实验完善组。观察各组的手术成功率和术后生存率以及手术并发症。
(2)采用改良二袖套法行Lewis大鼠到Brown Norway(BN)大鼠原位肝脏移植共30例,将其随机分成实验组15例,术后未进行特殊的干预,和对照组15例,术后1～7天用FK506 0.2mg/(kg.d)灌胃。术后4、7和10天的时间点上各组均随机处死3只受体大鼠,收集血清与肝脏标本,其余受体大鼠的血清标本通过舌静脉取血获得。血清标本检测细胞因子和生化指标,肝脏标本观察病理变化和肝细胞凋亡。每组各留6只观察术后生存情况及生存时间。
(3)将经过双酶切的hOX40片段和hIgG1 Fc片段与同样经过双酶切的pAdTrack-CMV载体进行连接反应,并在大肠杆菌感受态细胞里转化成pAdTrack-CMV-hOX40Ig转移质粒,再通过PCR扩增双酶切及DNA测序鉴定,经鉴定正确的质粒命名为pAdTrack-CMV-OX40Ig(pTOX40Ig)。
将pTOX40Ig转移质粒经PmeⅠ单酶切线性化后,与pAdeasy-1腺病毒载体氯化钙法共转化BJ5183感受态细胞,涂布卡那平板,挑选克隆、扩增,抽提质粒行PCR及PacⅠ酶切鉴定。
鉴定正确的重组腺病毒质粒pAdOX40Ig经PacⅠ酶切后,采用Lipofectamine2000脂质体转染法转染293A细胞,转染第3天在荧光显微镜下观察荧光。重组腺病毒AdOX40Ig通过Western印迹鉴定。
(4)将AdvOX40Ig重组腺病毒以1、10、25、50、100、200MOI不同剂量感染HL-7702细胞。在普通光镜视野下观察被感染后HL-7702细胞形态,在荧光视野下观察绿色荧光。
将AdvOX40Ig重组腺病毒和Ad空载体腺病毒以50MOI剂量分别感染爬片的HL-7702细胞,用免疫荧光染色试剂盒进行间接免疫荧光检测腺病毒介导的外源性OX40Ig基因在HL-7702细胞中的表达;用ELISA法测定转染AdvOX40Ig的HL-7702肝细胞培养上清。
(5)改良二袖套法行Lewis大鼠到Brown Norway(BN)大鼠原位肝脏移植40例,随机分成4组,每组10对。对照组:供、受体均未经任何处理,空载病毒AdEGFP处理组:术中供肝离体后肝内留存2ml的AdEGFP腺病毒[1×10~9pfu/ml],AdOX40Ig处理组:术中供肝离体后肝内留存2ml的AdOX40Ig腺病毒[1×10~9pfu/ml],FK506处理组:术后FK506(0.2mg·kg~(-1)·d~(-1))灌胃。
术后第7天每组各处死BN鼠3只,先经下腔静脉抽血,取部分血清,进行肝功能的检测,取肝脏,观察病理变化和肝细胞凋亡,取脾脏细胞与Lewis大鼠和第三品系F344大鼠的脾脏细胞进行单向混合淋巴细胞反应(MLR)。在BN大鼠与Lewis大鼠的MLR反应体系中,另取3个复孔,在每个复孔中加入20μl(1 IU/μl)重组IL_2。取四组处死BN大鼠的剩余血清及术前舌静脉采血取得的血清,采用双抗体夹心ABC-ELISA法来检测IFN-γ、IL-2、IL-4和IL-10的含量。余大鼠观察生存期,并且分别于病毒给予当天和第1、3、7、10、14、21和28天取大鼠尾静脉血,收集血清。用ELISA法检测血清中OX40Ig蛋白表达水平。
结果
(1)预试验组的手术成功率和7天生存率分别为27.5%和0;实验熟练组分别为75.0%和40.0%;实验完善组分别为93.3%和86.7%。
(2)手术的成功率是93.7%(30/32)。实验组大鼠在术后7～10天表现出明显的急性排斥症状。实验组的生存时间是9.17±1.17(天),而对照组是50.17±8.50(天)。实验组的肝功能(AST、ALT、TB)明显高于对照组。实验组术后第7天的血清IFN-γ和IL-2浓度明显高于术前,而IL-4和IL-10浓度则明显低于术前;对照组正好与此相反,术后第7天的血清IFN-γ和IL-2浓度明显低于术前,而IL-4和IL-10浓度明显高于术前。受体大鼠术后肝脏病理组织学检查发现,实验组术后第7天出现中度细胞性排斥,10天出现重度细胞性排斥,而对照组术后第7和第10天呈轻微细胞性排斥。此外,实验组肝细胞凋亡数较对照组显著增多。
(3)经酶切反应及DNA测序鉴定,重组腺病毒质粒pAdOX40Ig序列正确。重组腺病毒质粒pAdOX40Ig转染293A细胞,转染第3天在荧光显微镜下能观察到荧光。反复冻融的重组病毒子经多轮感染后,检测效价达到10~(10)pfu/ml。重组腺病毒AdOX40Ig的Western印迹鉴定可以看到48.7kD的条带。
(4)在普通光镜视野下观察1、10、25、50、100MOI不同剂量重组腺病毒感染组HL-7702细胞均形态正常,生长良好;而200MOI剂量感染组细胞圆缩、脱落,呈现明显的细胞毒性;在荧光视野下,10、25、50、100、200MOI不同剂量重组腺病毒感染组HL-7702细胞几乎所有细胞均可观察到绿色荧光。
AdvOX40Ig感染组HL-7702细胞能检测到Cy3红色荧光,而Ad空病毒感染组和未感染组HL-7702细胞则未出现红色荧光。ELISA测定显示,AdOX40Ig感染组细胞培养上清中OX40Ig浓度明显高于无病毒感染组和AdEGFP感染组。
(5)AdOX40Ig处理组和FK506处理组受体大鼠存活时间明显超过对照组和空载病毒AdEGFP处理组,肝功能(AST、ALT、TB)明显低于对照组和空载病毒AdEGFP处理组,肝细胞性排斥明显低于对照组和空载病毒AdEGFP处理组,肝细胞凋亡也明显少于对照组和空载病毒AdEGFP处理组。术后AdOX40Ig处理组和FK506处理组受体大鼠血清中IFN-γ、IL-2的含量较术前明显降低(P＜0.05),而IL-4和IL-10的含量则较术前明显升高(P＜0.05);对照组和空载病毒AdEGFP处理组大鼠肝移植术后排斥组血清中IFN-γ、IL-2的含量较术前明显升高(P＜0.05),而IL-4和IL-10的含量较术前明显降低(P＜0.05)。AdOX40Ig处理组和FK506处理组的CPM值均明显高于对照组和空载病毒AdEGFP处理组。在BN大鼠与Lewis大鼠的MLR反应体系中,加入重组IL-2,AdOX40Ig处理组和FK506处理组CPM值下降轻,与未加入重组IL-2的CPM值相比,差异有统计学意义。在BN大鼠与F344大鼠的MLR反应体系中,CPM值结果显示对照组、空载病毒AdEGFP处理组和AdOX40Ig处理组相互之间无统计学意义上的差异,但是这三组的CPM值均明显高于FK506处理组。
结论
(1)熟练和完善的外科操作技术是手术成功的关键;缩短无肝期时间是术后长期生存的有效保障。
(2)以近交系Lewis大鼠为供体、BN大鼠为受体的组合发生的急性排斥反应强烈而且稳定,是理想的大鼠肝脏移植急性排斥模型。
(3)重组腺病毒pAdOX40Ig构建成功,检测效价达到10~(10)pfu/ml。
(4)结果表明10、25、50、100MOI不同剂量病毒感染HL～7702细胞对细胞几乎无毒性,而且呈很高的感染效率,其可达90%以上,这提示10MOI为最佳感染剂量。间接免疫荧光检测结果和ELISA法测定结果均表明,腺病毒介导的外源性OX40基因能在HL-7702细胞中成功表达。
(5)用OX40Ig处理供肝具有FK506的抗急性排斥反应的功能,具体表现在,用AdOX40Ig处理的大鼠存活时间长,肝细胞性排斥轻,肝细胞凋亡少,肝功能损害轻,免疫反应向Th2细胞偏移,被抑制的混合淋巴细胞反应能够被IL-2逆转。用AdOX40Ig处理供肝,能够抑制用同品系大鼠的刺激细胞引起的混合淋巴细胞反应,但不能抑制用异品系大鼠的刺激细胞引起的混合淋巴细胞反应,这与FK506不同。
Objectives
(1) To set up a successful model of orthotopic liver transplantation in rats by modified two-cuffed technique..
(2) To set up an acute rejection model of orthotopic liver transplantation in rats by modified two-cuffed technique.
(3) To construct a recombinant adenovirus vector pAdeasy-1-pAdTrack-CMV-OX40Ig (AdOX40Ig).
(4) To determine the influence and infection efficiencies of different titers of AdOX40Ig recombinant adenovirus on the growth of human hepatocyte HL-7702,and select out the best titer to study on the biological function of the virus.
(5) To discuss the role and regime of adenovirus-mediated OX40Ig gene in inducing long-term survival of liver allografts in rats
Methods
(1) Orthotopic liver transplantation was conducted in 130 pairs of SD rats by modified two-cuffed technique.The first 40 pairs are the pre-experimental group,the middle 60 pairs are the experimentally skilled group,and the last 30 pairs are called the experimentally consummate group.The successful operative rate,the postoperative survival rate and the operative complications were observed.
(2) Thirty cases of Orthotopic liver transplantation was performed in Lewis to BN rats through the modified two-cuffed technique,and all rats were randomly divided into 2 equal groups.One was experimental group which were not specially treated,and the other was contrast group which took gastric perfusion with 0.2mg/(kg.d) FK506 during 1～7 days after operation.Each time on the 4th,5th and 10th days after transplantation,3 rats in either group were killed,whose blood and liver samples were collected while the other receptor rats' blood samples were drawn from their lingual vein.Blood samples were used for examining cytokine and biochemical indicators.Liver lobes were applied to detect pathological changes and liver cell apoptosis.The 6 survival rats in each group were used for recording postoperative living status and survival time.
(3) After double digestion,hOX40,hIgG1 Fc fragment and pAdTrack-CMV vector were connected for gene recombination,then transferred into competent E.coli cells and generated pAdTrack-CMV-hOX40Ig transfer plasmid.It was verified by PCR amplification,double-enzyme digestion and DNA sequencing,the correct plasmid named pAdTrack-CMV-OX40Ig(pTOX40Ig).
After linearization of transfer plasmid PTOX40Ig,the plasmid was co-infected with pAdeasy-1 adenovirus vector into competent BJ5183 cells by the method of calcium chloride.Then the cells were coated on the tablet containing kanamycin.Correct clone was selected by extraction of plasmid,and thereafter PCR and restriction enzyme digestion by PacⅠfor verification.
The correct recombinant plasmid pAdOX40Ig was transfected into 293A cells by using Lipofectamine 2000 after digested by PacⅠ.On the third day after tansfection,the fluorescence was observed under fluorescence microscope.The recombinant adenovirus AdOX40Ig was also identified by Western blot.
(4) Recombinant adenovirus AdvOX40Ig infected HL-7702 cells at different titer such as 1,10,25,50,100,200 MOI.Cell morphology of infected HL-7702 was observed under light microscope,and the green fluorescent was observed under the fluorescent vision.
AdvOX40Ig recombinant adenovirus and mock adenovirus were infected into HL-7702 cells at 50MOI dose respectively.Adenovirus-mediated exogenous gene OX40Ig expression in HL-7702 cells was detected through indirect immunofluorescence by immunofluorescent staining kit.ELISA method was also used to determine the concentration in the culture supernatant after HL-7702 liver cells infected with adenovirus AdvOX40Ig.
(5) Forty cases of Orthotopic liver transplantation was performed in Lewis to BN rats through the modified two-cuffed technique,and all rats were randomly divided into 4 equal groups:contrast group(neither donors nor receptors were treated),AdEGFP treated group (donor liver carried 2ml adenovirus AdEGFP[1×10~9pfu/ml]after it was excised during operation,AdOX40Ig treated group(donor liver carried 2ml adenovirus AdOX40Ig [1×10~9pfu/ml]after it was excised during operation),and FKS06 treated group(gastric perfusion with FK506(0.2mg·kg~(-1)·d~(-1)) after operation).
On the 7th day after operation,3 BN rats in each group were killed.Blood was then drawn from the inferior caval vein to detect the liver funtion.Liver was excised to detect pathological changes and liver cell apoptosis.Spleen cells were collected to undergo mixed lymphocyte reaction(MLR) with the Lewis rats and the third strain F344 rats' spleen cells. Three repeated holes were prepared in the MLR process between BN rats and Lewis rats among which each was mixed with 20μl(1 IU/μl) Recombinant IL-2.With the remaining blood of the 4-group killed BN rats and the blood preoperatively drawn from lingual vein, the content of IFN-γ,IL-2,IL-4 and IL-10 was detected by double antibody sandwiched ABC-ELISA procedure.The survival rats were used to detect live range,and their blood was collected from caudal vein on the day virus was planted and on the 1st,3rd,7th,10th, 14th,21th and 28th days after that treatment.The OX40Ig protein expression level was assayed ELISA procedure.
Results
(1) The successful operative rate and the 7-day survival rate were respectively 27.5% and 0 in the pre-experimental group,75.0%and 40.0%in the experimentally skilled group, and 93.3%and 86.7%in the experimentally consummate group.
(2) The successful operative rate was 93.7%(30/32).The experimental group of rats exhibited obvious acute rejection on the 7th～10th days after operation.The live range was 9.17±1.17 days for the experimental group and 50.17±8.50 days for the contrast group.The liver function of the experimental goup was obviously better than that of the control group. As for the experimental group,the content of IFN-γrand IL-2 on the 7th postoperative day was significantly more than that in the preoperative time,vice versa for IL-4 and IL-10.As for the contrast group,the result was opposite.The postoperative hepatic pathological results showed that medium and severe cellular rejection turned up respectively on the 7th and 10th postoperative days in the experimental group while in the contrast group mild cellular rejection turned up on the same days.The liver cell apoptosis was distinctively more severe in the experimental group than that in the contrast group.
(3) By enzyme digestion and DNA sequencing,the sequence of recombinant adenovirus vector pAdOX40Ig was proved to be correct.In infection of 293A cells,could be seen on the third after transfection.After several rounds of infection of recombinant virus,testing titer reached 10~(10)pfu/ml.A strip of 48.7kD could be seen from Western blot on identification of recombinant AdOX40Ig.
(4) Under light microscope,recombinant adenovirus infected HL-7702 cells at 1,10,25,50,100 MOI of different doses were morphologically normal,grow well,and infected cells at 200MOI were round shrinkage and off shown clear signs of cell toxicity. At fluorescence Perspective,the green fluorescence were almost all could be observed in recombinant adenovirus infected HL-7702 cells at 10,25,50,100,200 MOI.
AdvOX40Ig infected HL-7702 cells could be detected with the Cy3 red fluorescence, while the mock virus infection group and non-infection group HL-7702 cells couldn't be seen in red fluorescence.Determination of ELISA results showed that,AdOX40Ig infection group was significantly higher than non-infected group and AdEGFP infected group.
(5) The living range of rats in the AdOX40Ig and FK506 treated groups was obviously longer than that in the control and AdEGFP treated groups,while the hepatic function of the previous groups was worse than that of the latter groups,the previous' hepatic cellular rejection was obviously milder than the latter's,and the previous' liver cell apoptosis was less than the latter's.The content of IFN-γand IL-2 in the blood after operation was obviously lower than that before operation(P＜0.05),vice versa for the content of IL-4 and IL-10(P＜0.05) in the AdOX40Ig and FK506 treated groups.As for the contrast and AdEGFP treated grous,the the postoperative content of IFN-γand IL-2 was obviously higher than before operation(P＜0.05) while the postoperative content of IL-4 and IL-10 was obviously lower than before operation P＜0.05).The CPM indexes of the AdOX40Ig and FK506 treated groups were obviously higher than that of the contrast and AdEGFP treated groups.With respect to the MLR reaction between BN rats and Lewis rats,the CPM indexes of AdOX40Ig and FK506 treated groups were significantly higher when the MLR was mixed with recombinant IL-2 than when the MLR was not mixed with recombinant IL-2.As for the MLR reaction between BN rats and F344 rats,there's statistically no meaning in comparison between each other about the CPM indexes of contrast,AdEGFP and AdOX40Ig treated groups.Nevertheless,the CPM indexes of the three groups were significantly higher than the FK506 group.
Conclusions
(1) The skilled and consummate surgical operative technique is key to successful operations.Shortening the anhepatic period efficiently ensures the long-term survival after operation.
(2) The acute rejection reaction between Lewis rats as donors and BN rats as receptors was fierce and stable,and thereof,an ideal acute rejection model for liver transplantation in rats.
(3) The recombinant adenovirus pAdOX40Ig was successfully constructed and the titer of virus was 10~(10)pfu/ml.
(4) Our results showed that different titers of virus such as 10,25,50,100MOI were not only non-toxic to cells but with high infection efficiency ahnost up to 90%.All these showed that 10MOI maybe the best infection titer.The results of indirect immunofluorescence test and ELISA showed that adenovirus induced exogenous OX40 gene expressed successfully in HL-7702 cells.
(5) The donor liver with OX40Ig treatment had the function of countering acute rejection,just like FK506.Specifically,the rats with AdOX40Ig treatment had a longer living range,milder hepatic cellular rejection,less hepatic cellular apoptosis,lighter harm to hepatic function,immunoreaction toward Th2 shift,and reversibility of depressed mixed lymphocyte reaction by IL-2.Unlike FK506,the donor liver with AdOX40Ig treatment could depress mixed lymphocyte reaction induced by activating cells of the same strain rats but could not depress mixed lymphocyte reaction induced by activating cells of rats of different stains.
(1)改良二袖套法大鼠原位肝脏移植动物模型的成功建立。
(2)改良二袖套法大鼠原位肝脏移植急性排斥动物模型的建立。
(3)重组腺病毒pAdeasy-1-pAdTrack-CMV-OX40Ig(AdOX40Ig)的构建
(4)研究重组腺病毒AdOX40Ig不同感染剂量对人肝细胞HL-7702生长的影响及其感染效率,筛选最佳感染剂量进行该重组腺病毒的生物学功能研究。
(5)探讨腺病毒介导OX40Ig基因转移在诱导大鼠肝脏移植物长期存活中的作用和机制。
方法
(1)通过改良的双袖套法对130对SD大鼠进行了原位肝移植。前面40对为预试验组,中间60对为实验熟练组,后面30对为实验完善组。观察各组的手术成功率和术后生存率以及手术并发症。
(2)采用改良二袖套法行Lewis大鼠到Brown Norway(BN)大鼠原位肝脏移植共30例,将其随机分成实验组15例,术后未进行特殊的干预,和对照组15例,术后1～7天用FK506 0.2mg/(kg.d)灌胃。术后4、7和10天的时间点上各组均随机处死3只受体大鼠,收集血清与肝脏标本,其余受体大鼠的血清标本通过舌静脉取血获得。血清标本检测细胞因子和生化指标,肝脏标本观察病理变化和肝细胞凋亡。每组各留6只观察术后生存情况及生存时间。
(3)将经过双酶切的hOX40片段和hIgG1 Fc片段与同样经过双酶切的pAdTrack-CMV载体进行连接反应,并在大肠杆菌感受态细胞里转化成pAdTrack-CMV-hOX40Ig转移质粒,再通过PCR扩增双酶切及DNA测序鉴定,经鉴定正确的质粒命名为pAdTrack-CMV-OX40Ig(pTOX40Ig)。
将pTOX40Ig转移质粒经PmeⅠ单酶切线性化后,与pAdeasy-1腺病毒载体氯化钙法共转化BJ5183感受态细胞,涂布卡那平板,挑选克隆、扩增,抽提质粒行PCR及PacⅠ酶切鉴定。
鉴定正确的重组腺病毒质粒pAdOX40Ig经PacⅠ酶切后,采用Lipofectamine2000脂质体转染法转染293A细胞,转染第3天在荧光显微镜下观察荧光。重组腺病毒AdOX40Ig通过Western印迹鉴定。
(4)将AdvOX40Ig重组腺病毒以1、10、25、50、100、200MOI不同剂量感染HL-7702细胞。在普通光镜视野下观察被感染后HL-7702细胞形态,在荧光视野下观察绿色荧光。
将AdvOX40Ig重组腺病毒和Ad空载体腺病毒以50MOI剂量分别感染爬片的HL-7702细胞,用免疫荧光染色试剂盒进行间接免疫荧光检测腺病毒介导的外源性OX40Ig基因在HL-7702细胞中的表达;用ELISA法测定转染AdvOX40Ig的HL-7702肝细胞培养上清。
(5)改良二袖套法行Lewis大鼠到Brown Norway(BN)大鼠原位肝脏移植40例,随机分成4组,每组10对。对照组:供、受体均未经任何处理,空载病毒AdEGFP处理组:术中供肝离体后肝内留存2ml的AdEGFP腺病毒[1×10~9pfu/ml],AdOX40Ig处理组:术中供肝离体后肝内留存2ml的AdOX40Ig腺病毒[1×10~9pfu/ml],FK506处理组:术后FK506(0.2mg·kg~(-1)·d~(-1))灌胃。
术后第7天每组各处死BN鼠3只,先经下腔静脉抽血,取部分血清,进行肝功能的检测,取肝脏,观察病理变化和肝细胞凋亡,取脾脏细胞与Lewis大鼠和第三品系F344大鼠的脾脏细胞进行单向混合淋巴细胞反应(MLR)。在BN大鼠与Lewis大鼠的MLR反应体系中,另取3个复孔,在每个复孔中加入20μl(1 IU/μl)重组IL_2。取四组处死BN大鼠的剩余血清及术前舌静脉采血取得的血清,采用双抗体夹心ABC-ELISA法来检测IFN-γ、IL-2、IL-4和IL-10的含量。余大鼠观察生存期,并且分别于病毒给予当天和第1、3、7、10、14、21和28天取大鼠尾静脉血,收集血清。用ELISA法检测血清中OX40Ig蛋白表达水平。
结果
(1)预试验组的手术成功率和7天生存率分别为27.5%和0;实验熟练组分别为75.0%和40.0%;实验完善组分别为93.3%和86.7%。
(2)手术的成功率是93.7%(30/32)。实验组大鼠在术后7～10天表现出明显的急性排斥症状。实验组的生存时间是9.17±1.17(天),而对照组是50.17±8.50(天)。实验组的肝功能(AST、ALT、TB)明显高于对照组。实验组术后第7天的血清IFN-γ和IL-2浓度明显高于术前,而IL-4和IL-10浓度则明显低于术前;对照组正好与此相反,术后第7天的血清IFN-γ和IL-2浓度明显低于术前,而IL-4和IL-10浓度明显高于术前。受体大鼠术后肝脏病理组织学检查发现,实验组术后第7天出现中度细胞性排斥,10天出现重度细胞性排斥,而对照组术后第7和第10天呈轻微细胞性排斥。此外,实验组肝细胞凋亡数较对照组显著增多。
(3)经酶切反应及DNA测序鉴定,重组腺病毒质粒pAdOX40Ig序列正确。重组腺病毒质粒pAdOX40Ig转染293A细胞,转染第3天在荧光显微镜下能观察到荧光。反复冻融的重组病毒子经多轮感染后,检测效价达到10~(10)pfu/ml。重组腺病毒AdOX40Ig的Western印迹鉴定可以看到48.7kD的条带。
(4)在普通光镜视野下观察1、10、25、50、100MOI不同剂量重组腺病毒感染组HL-7702细胞均形态正常,生长良好;而200MOI剂量感染组细胞圆缩、脱落,呈现明显的细胞毒性;在荧光视野下,10、25、50、100、200MOI不同剂量重组腺病毒感染组HL-7702细胞几乎所有细胞均可观察到绿色荧光。
AdvOX40Ig感染组HL-7702细胞能检测到Cy3红色荧光,而Ad空病毒感染组和未感染组HL-7702细胞则未出现红色荧光。ELISA测定显示,AdOX40Ig感染组细胞培养上清中OX40Ig浓度明显高于无病毒感染组和AdEGFP感染组。
(5)AdOX40Ig处理组和FK506处理组受体大鼠存活时间明显超过对照组和空载病毒AdEGFP处理组,肝功能(AST、ALT、TB)明显低于对照组和空载病毒AdEGFP处理组,肝细胞性排斥明显低于对照组和空载病毒AdEGFP处理组,肝细胞凋亡也明显少于对照组和空载病毒AdEGFP处理组。术后AdOX40Ig处理组和FK506处理组受体大鼠血清中IFN-γ、IL-2的含量较术前明显降低(P＜0.05),而IL-4和IL-10的含量则较术前明显升高(P＜0.05);对照组和空载病毒AdEGFP处理组大鼠肝移植术后排斥组血清中IFN-γ、IL-2的含量较术前明显升高(P＜0.05),而IL-4和IL-10的含量较术前明显降低(P＜0.05)。AdOX40Ig处理组和FK506处理组的CPM值均明显高于对照组和空载病毒AdEGFP处理组。在BN大鼠与Lewis大鼠的MLR反应体系中,加入重组IL-2,AdOX40Ig处理组和FK506处理组CPM值下降轻,与未加入重组IL-2的CPM值相比,差异有统计学意义。在BN大鼠与F344大鼠的MLR反应体系中,CPM值结果显示对照组、空载病毒AdEGFP处理组和AdOX40Ig处理组相互之间无统计学意义上的差异,但是这三组的CPM值均明显高于FK506处理组。
结论
(1)熟练和完善的外科操作技术是手术成功的关键;缩短无肝期时间是术后长期生存的有效保障。
(2)以近交系Lewis大鼠为供体、BN大鼠为受体的组合发生的急性排斥反应强烈而且稳定,是理想的大鼠肝脏移植急性排斥模型。
(3)重组腺病毒pAdOX40Ig构建成功,检测效价达到10~(10)pfu/ml。
(4)结果表明10、25、50、100MOI不同剂量病毒感染HL～7702细胞对细胞几乎无毒性,而且呈很高的感染效率,其可达90%以上,这提示10MOI为最佳感染剂量。间接免疫荧光检测结果和ELISA法测定结果均表明,腺病毒介导的外源性OX40基因能在HL-7702细胞中成功表达。
(5)用OX40Ig处理供肝具有FK506的抗急性排斥反应的功能,具体表现在,用AdOX40Ig处理的大鼠存活时间长,肝细胞性排斥轻,肝细胞凋亡少,肝功能损害轻,免疫反应向Th2细胞偏移,被抑制的混合淋巴细胞反应能够被IL-2逆转。用AdOX40Ig处理供肝,能够抑制用同品系大鼠的刺激细胞引起的混合淋巴细胞反应,但不能抑制用异品系大鼠的刺激细胞引起的混合淋巴细胞反应,这与FK506不同。
Objectives
(1) To set up a successful model of orthotopic liver transplantation in rats by modified two-cuffed technique..
(2) To set up an acute rejection model of orthotopic liver transplantation in rats by modified two-cuffed technique.
(3) To construct a recombinant adenovirus vector pAdeasy-1-pAdTrack-CMV-OX40Ig (AdOX40Ig).
(4) To determine the influence and infection efficiencies of different titers of AdOX40Ig recombinant adenovirus on the growth of human hepatocyte HL-7702,and select out the best titer to study on the biological function of the virus.
(5) To discuss the role and regime of adenovirus-mediated OX40Ig gene in inducing long-term survival of liver allografts in rats
Methods
(1) Orthotopic liver transplantation was conducted in 130 pairs of SD rats by modified two-cuffed technique.The first 40 pairs are the pre-experimental group,the middle 60 pairs are the experimentally skilled group,and the last 30 pairs are called the experimentally consummate group.The successful operative rate,the postoperative survival rate and the operative complications were observed.
(2) Thirty cases of Orthotopic liver transplantation was performed in Lewis to BN rats through the modified two-cuffed technique,and all rats were randomly divided into 2 equal groups.One was experimental group which were not specially treated,and the other was contrast group which took gastric perfusion with 0.2mg/(kg.d) FK506 during 1～7 days after operation.Each time on the 4th,5th and 10th days after transplantation,3 rats in either group were killed,whose blood and liver samples were collected while the other receptor rats' blood samples were drawn from their lingual vein.Blood samples were used for examining cytokine and biochemical indicators.Liver lobes were applied to detect pathological changes and liver cell apoptosis.The 6 survival rats in each group were used for recording postoperative living status and survival time.
(3) After double digestion,hOX40,hIgG1 Fc fragment and pAdTrack-CMV vector were connected for gene recombination,then transferred into competent E.coli cells and generated pAdTrack-CMV-hOX40Ig transfer plasmid.It was verified by PCR amplification,double-enzyme digestion and DNA sequencing,the correct plasmid named pAdTrack-CMV-OX40Ig(pTOX40Ig).
After linearization of transfer plasmid PTOX40Ig,the plasmid was co-infected with pAdeasy-1 adenovirus vector into competent BJ5183 cells by the method of calcium chloride.Then the cells were coated on the tablet containing kanamycin.Correct clone was selected by extraction of plasmid,and thereafter PCR and restriction enzyme digestion by PacⅠfor verification.
The correct recombinant plasmid pAdOX40Ig was transfected into 293A cells by using Lipofectamine 2000 after digested by PacⅠ.On the third day after tansfection,the fluorescence was observed under fluorescence microscope.The recombinant adenovirus AdOX40Ig was also identified by Western blot.
(4) Recombinant adenovirus AdvOX40Ig infected HL-7702 cells at different titer such as 1,10,25,50,100,200 MOI.Cell morphology of infected HL-7702 was observed under light microscope,and the green fluorescent was observed under the fluorescent vision.
AdvOX40Ig recombinant adenovirus and mock adenovirus were infected into HL-7702 cells at 50MOI dose respectively.Adenovirus-mediated exogenous gene OX40Ig expression in HL-7702 cells was detected through indirect immunofluorescence by immunofluorescent staining kit.ELISA method was also used to determine the concentration in the culture supernatant after HL-7702 liver cells infected with adenovirus AdvOX40Ig.
(5) Forty cases of Orthotopic liver transplantation was performed in Lewis to BN rats through the modified two-cuffed technique,and all rats were randomly divided into 4 equal groups:contrast group(neither donors nor receptors were treated),AdEGFP treated group (donor liver carried 2ml adenovirus AdEGFP[1×10~9pfu/ml]after it was excised during operation,AdOX40Ig treated group(donor liver carried 2ml adenovirus AdOX40Ig [1×10~9pfu/ml]after it was excised during operation),and FKS06 treated group(gastric perfusion with FK506(0.2mg·kg~(-1)·d~(-1)) after operation).
On the 7th day after operation,3 BN rats in each group were killed.Blood was then drawn from the inferior caval vein to detect the liver funtion.Liver was excised to detect pathological changes and liver cell apoptosis.Spleen cells were collected to undergo mixed lymphocyte reaction(MLR) with the Lewis rats and the third strain F344 rats' spleen cells. Three repeated holes were prepared in the MLR process between BN rats and Lewis rats among which each was mixed with 20μl(1 IU/μl) Recombinant IL-2.With the remaining blood of the 4-group killed BN rats and the blood preoperatively drawn from lingual vein, the content of IFN-γ,IL-2,IL-4 and IL-10 was detected by double antibody sandwiched ABC-ELISA procedure.The survival rats were used to detect live range,and their blood was collected from caudal vein on the day virus was planted and on the 1st,3rd,7th,10th, 14th,21th and 28th days after that treatment.The OX40Ig protein expression level was assayed ELISA procedure.
Results
(1) The successful operative rate and the 7-day survival rate were respectively 27.5% and 0 in the pre-experimental group,75.0%and 40.0%in the experimentally skilled group, and 93.3%and 86.7%in the experimentally consummate group.
(2) The successful operative rate was 93.7%(30/32).The experimental group of rats exhibited obvious acute rejection on the 7th～10th days after operation.The live range was 9.17±1.17 days for the experimental group and 50.17±8.50 days for the contrast group.The liver function of the experimental goup was obviously better than that of the control group. As for the experimental group,the content of IFN-γrand IL-2 on the 7th postoperative day was significantly more than that in the preoperative time,vice versa for IL-4 and IL-10.As for the contrast group,the result was opposite.The postoperative hepatic pathological results showed that medium and severe cellular rejection turned up respectively on the 7th and 10th postoperative days in the experimental group while in the contrast group mild cellular rejection turned up on the same days.The liver cell apoptosis was distinctively more severe in the experimental group than that in the contrast group.
(3) By enzyme digestion and DNA sequencing,the sequence of recombinant adenovirus vector pAdOX40Ig was proved to be correct.In infection of 293A cells,could be seen on the third after transfection.After several rounds of infection of recombinant virus,testing titer reached 10~(10)pfu/ml.A strip of 48.7kD could be seen from Western blot on identification of recombinant AdOX40Ig.
(4) Under light microscope,recombinant adenovirus infected HL-7702 cells at 1,10,25,50,100 MOI of different doses were morphologically normal,grow well,and infected cells at 200MOI were round shrinkage and off shown clear signs of cell toxicity. At fluorescence Perspective,the green fluorescence were almost all could be observed in recombinant adenovirus infected HL-7702 cells at 10,25,50,100,200 MOI.
AdvOX40Ig infected HL-7702 cells could be detected with the Cy3 red fluorescence, while the mock virus infection group and non-infection group HL-7702 cells couldn't be seen in red fluorescence.Determination of ELISA results showed that,AdOX40Ig infection group was significantly higher than non-infected group and AdEGFP infected group.
(5) The living range of rats in the AdOX40Ig and FK506 treated groups was obviously longer than that in the control and AdEGFP treated groups,while the hepatic function of the previous groups was worse than that of the latter groups,the previous' hepatic cellular rejection was obviously milder than the latter's,and the previous' liver cell apoptosis was less than the latter's.The content of IFN-γand IL-2 in the blood after operation was obviously lower than that before operation(P＜0.05),vice versa for the content of IL-4 and IL-10(P＜0.05) in the AdOX40Ig and FK506 treated groups.As for the contrast and AdEGFP treated grous,the the postoperative content of IFN-γand IL-2 was obviously higher than before operation(P＜0.05) while the postoperative content of IL-4 and IL-10 was obviously lower than before operation P＜0.05).The CPM indexes of the AdOX40Ig and FK506 treated groups were obviously higher than that of the contrast and AdEGFP treated groups.With respect to the MLR reaction between BN rats and Lewis rats,the CPM indexes of AdOX40Ig and FK506 treated groups were significantly higher when the MLR was mixed with recombinant IL-2 than when the MLR was not mixed with recombinant IL-2.As for the MLR reaction between BN rats and F344 rats,there's statistically no meaning in comparison between each other about the CPM indexes of contrast,AdEGFP and AdOX40Ig treated groups.Nevertheless,the CPM indexes of the three groups were significantly higher than the FK506 group.
Conclusions
(1) The skilled and consummate surgical operative technique is key to successful operations.Shortening the anhepatic period efficiently ensures the long-term survival after operation.
(2) The acute rejection reaction between Lewis rats as donors and BN rats as receptors was fierce and stable,and thereof,an ideal acute rejection model for liver transplantation in rats.
(3) The recombinant adenovirus pAdOX40Ig was successfully constructed and the titer of virus was 10~(10)pfu/ml.
(4) Our results showed that different titers of virus such as 10,25,50,100MOI were not only non-toxic to cells but with high infection efficiency ahnost up to 90%.All these showed that 10MOI maybe the best infection titer.The results of indirect immunofluorescence test and ELISA showed that adenovirus induced exogenous OX40 gene expressed successfully in HL-7702 cells.
(5) The donor liver with OX40Ig treatment had the function of countering acute rejection,just like FK506.Specifically,the rats with AdOX40Ig treatment had a longer living range,milder hepatic cellular rejection,less hepatic cellular apoptosis,lighter harm to hepatic function,immunoreaction toward Th2 shift,and reversibility of depressed mixed lymphocyte reaction by IL-2.Unlike FK506,the donor liver with AdOX40Ig treatment could depress mixed lymphocyte reaction induced by activating cells of the same strain rats but could not depress mixed lymphocyte reaction induced by activating cells of rats of different stains.
引文
[1]Dawwas MF,Gimson AE,Lewsey JD,et al.Survival after liver transplantation in the United Kingdom and Ireland compared with the United States.Gut,2007,56(11):1606-1613.
[2]Perrella O,Sbreglia C,Arenga G,et al.Acute rejection after live transplantation:Is there a specific immunological pattern?Transplant Proc,2006,38(10):3594-3596.
[3]Michel F,Attal Bonnefoy G,Mangino G,et al.CD28 as a molecular amplifier extending TCR ligation and signaling capaling capabilities.Immunity,2001,15(6):935-945.
[4]Sugamttra K,Ishii N,Weinberg A.Therapeutic targeting of the effect T-cell co-stimulatory molecule OX40.Nature Reviews Immunology,2004,4:420-431.
[5]Chen AI,McAdam AJ,Buhlmann JE,et al.OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.Immtmity,1999,11:689-698.
[6]Murata K,Ishii N,Takano H,et al.Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.J Exp Med,2000,191:365-374.
[7]Zabairi S,Sanos SL,Hill S,et al.Immunotherapy with OX40L-Fc or anti-CTLA4enhances local tissue responses and killing of leishmania donovan.Eur J Immunol,2004,34:1433-1440.
[8]Weinberg AD.OX40:targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines[J].Trends Immunol,2002,23(2):102-109.
[9]Kotani A,Ishikawa T,MatsumuraY,et al.Correlation of peripheral blood OX40~+(CD134~+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation[J].Blood,2001,98(10):3162-3164.
[10]Demirci G,Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28and CD154-independent rejection[J].J Immnunol,2004,172(3):1691-1698.
[11]AB Adams,TR Jones,EA Heiss,et al.The CD134/CD134L pathway is critical in CD8-mediated costimulation blockade resistant rejection.Transplantation,2004,78(2):Supplement 1:181.
[12]Allison J.Curry,Jo Chikwe,Xin G.Smith,et al.OX40(CD134) Blockade Inhibits the Co-stimulatory Cascade and Promotes Heart Allograft Survival.Transplantation,2004,78(6):807-814.
[13]王光明,杨阳,李爱玲,等.CTLA4Ig和OX40Ig的表达及其生物学活性研究.中华微生物学和免疫学杂志,2005,25(5):383-387.
[14]王光明,孙涛,张元元,等.腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用.中华医学杂志,2005,85(48):3435-3439.
[1]余斌,秦磊,钱海鑫.大鼠肝移植的麻醉.苏州大学学报(医学版),2005,25(2):245-247.
[2]彭勇,龚建平,严律南.大鼠原位肝移植模型制作过程中麻醉方法的选择.中国普通外科杂志,2003,12:673-676.
[3]Lee S,Charters C,Chandler J,Orloff M.A technique for orthotopic liver transplantation in the rat,Transplantation,1973,16:664-669.
[4]Lee S,Chaners C,Orloff M.Simplified technique for Orthotopic liver transplantation in the rat.Am J Surg,1975,130:38-40.
[5]Kamada N,Calne RY.Orthotopic liver transplantation in the rat.Transplantation,1979,28:47-50.
[6]Zimmerman FA,Butcher GW,Davies HS,et al.Techniques for orthotopic liver transplantation in the rat and some studies of the immunologic responses to fully allogenetic liver grafts.Transplant Proc,1979,11:571-574.
[7]Kamada N,Calne R,A surgical experience with five hundred thirty liver transplantation in the rat.Surgery,1983,93:64-69.
[8]Miyata M,Fisher J,Fuhs M.et al A simple method for orthotopic liver transplantation in the rat.Transplantation 1980;30:335-338.
[9]Hasuike Y,Monden M,Valdivia LA,et al A simple method for orthotopic liver transplantation with arterial reconstruction in rats.Transplantation 1988,45:830-832.
[10]Steffen R,Ferguson DM,Krom RAF A new method orthotopic rat liver transplantation with arterial cuff anastomosis to the recipient common hepatic artery. Transplantation 1989,48: 166-168.
[11] Howden B, Jabronski P,Grossman H, et al The importance of the hepatic artery in rat liver transplantation. Transplantation 1989,47: 428-431.
[12] Chaland P.Braillon A, Gaudin C, et al Orthotopic liver transplantation with hepatic artery Transplantation 1990, 49: 675-679.
[13] Liu L, Freise CE, Ferell L, et al A modified vascular "sleeve" anastomoses for rearterialization in orthotopic liver transplantation in the rats Transplantation 1992, 54:179-180.
[14] Knoop M, Bachmann S, Keck H, et al Experience with cuff rearterialization in 600 Orthotopic liver grafts in the rat. Am J Surg 1994,167: 360-363.
[1]Banff schema for grading liver allograft rejection:an international consensus document.Hepatology,1997,25(3):658-663.
[2]Lee S,Charters AC,Chandler JG,et al.A technique for orthotopic liver transplantation in the rat[J].Transplantation,1973,16:664-669.
[3]Kamada N,Calne RY.Orthotopic liver transplantation in the rat.Techniques using cuff for portal vein anastomosis and biliary drainage[J].Transplantation,1979,28(1):47-49.
[4]Kamada N,Calne RY.A surgical experiment with five hundred thirty liver transplants in the rat[J].Surgery,1983,93(1):64-69.
[5]Zimmermann FA,et al.The fate of Orthotopic liver allografts in different rat strain combination[J]Transp Proc,1983,15:1272.
[6]邵义祥 医学实验动物学.东南大学出版社,2003:12。
[7]龚非力.医学免疫学.北京:科学出版社.2003,101。
[8]Mosmann TR,Sad S.The expandind universe of T-cell subsets:Th1,Th2 and more[J].Immunol Today,1996,17:138-146.
[9]Neuberger J.Liver allograft rejection-current concepts on diagnosis and treatment[J].J Hepatol.1995,23(suppl 1):54-61.
[10]许赤,黄洁夫,陈规划,等。大鼠肝移植术后早期急性排斥反应与细胞因子基因表达的关系 [J]。肝胆外科杂志,2000,8(3):229-230。
[11]Boecolo P,et al.The immune response of women with prolonged exposure to electromagnetic fields produced by radiotelevision broadcasting stations.Int J Immunopathol Pharmacol.2006,19(4):43.
[12]Furukawa Y,Becker G,Stinn L,et al.Interleukin-10 augments allograft arterial disease:paradoxical effects of IL-10 in vivo[J].Am J Patnol,1999,155:1929-1939.
[13]DM Plaza,D Fernandez,M Builes,et al.Cytokine gene polymorphisms in heart transplantation:association of low IL-10 production genotype with quilty effect[J].J Heart Lung Transplant,2003,22(8):851-856.
[14]邹晓明,杨维良,姜学海,等。RhIL-10在大鼠肝移植再灌注损伤和急性排斥反应中的作用[J]。中华普通外科杂志,2002,17(2):96-98。
[15]Qin L,Ding Y,Tahara H,et al.Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft[J].Immunol.2001,166:2385-2393.
[16]芮晓辉,蔡端,张群华,等。TNF-α和IL-10在非协调性异种肝移植中的作用探讨[J]。中华肝胆外科杂志,2002,8(11):680-682。
[17]王光明,孙涛,张元元,等。腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用[J]。中华医学杂志,2005,85(48):3435-3439。
[18]Qian S,Lu L,Fu F,et al.Apoptosis within spontaneously accepted mouse liver allografts[J].J Immunol,1997,158:4654-4661.
[19]Shintaku S,Ohdan H,et al.Expression of bcl-2 homologue mRNAs in rat liver allograft:rejection -induced cell apoptosis is associated with up-regulation of bax and bcl-xs expression[J].Transplant Int,1998,11(Suppl):284-288.
[20]Tannapfel A,Kohlhaw K,Ebelt J,et al.Apoptosis and the expression of Fas and Fas ligand(FasL)antigen in rejection and reinfection in liver allograft specimens[J].Transplantation,1999,67(7):1079-1083.
[21]刘玉兰,刘峰,孙君泓。Fas/FasL表达和细胞凋亡在大鼠同种异体肝移植免疫中的作用[J]。中华普通外科杂志,2003,18(2):99-101。
[22]Maciejewski J,Selleri C,Anderson S,et al.Fas antigen expression on CD34+human marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro[J].Blood,1995,85(11):3183-3190.
[23]Xu X,Fu xy,P late J,et al.IFN-gamma induce cell growth inhibition by Fas-mediated apoptosis:requirement of STAT1 protein for up-regulation of Fas and FasL expression[J].Cancer Res,1998,58(13):2832-2837.
[1]Jeffrey M.Isner,Peter R.Vale,James F.Symes,et al.Assessment of risks associated with cardiovascular gene therapy in human subjects.Circ Res.2001,89:389-400.
[2]Nielsen LL,Gurnani M,Syed L,et al.Recombinant E1-deleted adenovirus mediated gene therapy for cancer efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Human gene therapy,1998,9:681-694.
[3]Kremer EJ,Perricaudet M.Adenovirus and adenovirus associated virus mediated gene transfer.Brit Med Bull,1995,51:31-44.
[4]French BA,Mazur W,Geske RS,et al.Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors.Circulation,1994,90:革者2414-2424.
[5]F.奥斯伯 等著,颜子颖 等译.精编分子生物学实验指南.北京:科学技术出版所,1998:276.
[1]Melillo G,Scoccianti M,Lovesdi I,et al.Gene therapy for collateral vessel de2velopment.Cardiovascular Res,1997,35(2):480-489.
[2]Yl(a|¨)-Herttuala S.Vascular gene tranfer.Curr Opin Lipidol,1997,8:72-76.
[3]Jeffrey M.Isner,Peter R.Vale,James F.Symes,et al.Assessment of risks associated with cardiovascular gene therapy in human subjects.Circ Res.2001,89:389-400.
[4]Nielsen LL,Gurnani M,Syed L,et al.Recombinant E1-deleted adenovirus mediated gene therapy for cancer efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Human gene therapy,1998,9:681-694.
[5]Kremer EJ,Perricaudet M.Adenovirus and adenovirus associated virus mediated gene transfer.Brit Med Bull,1995,51:31-44.
[6]Hong SS,Karayan L,Toumier J,et al.Adenovirus type 5fiber knob binds to MHC cIass Ⅰα2 domain at the surface of human epithelial and B lymphoblastoid cells.EMBOJ,1997,16:2291-2306.
[7]Kass-eisler A,Falck-pedersen E,Alvira M,et al.Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo.Proc Nati Acad Sci USA,1993,90:11498-11502.
[1]Dawwas MF,Gimson AE,Lewsey JD,et al.Survival after liver transplantation in the United Kingdom and Ireland compared with the United States.Gut,2007,56(11):1606-1613.
[2] PeiTella O,Sbreglia C,Arenga G,et al.Acute rejection after live transplantation: Is there a specific immunological pattern?Transplant Proc.2006; 38(10): 3594-3596.
[3] Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids(3 day taper). Liver Transplant, 2001, 7(4): 343-351.
[4] Barsher NR Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci, 2004, 9:411-420.
[5] Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs, 2002; 62(7): 995-1011.
[6] Vincenti F, Larsen C, Durrbach A. Costimulation blockade with belatacept in renal transplantation. N Engl Med, 2005, 353(8): 770-781.
[7] changelian PS,Flanagan ME, Ball DJ,et al. Science, 2003. 302(5646): 875-878.
[8] Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation,2004,77(12): 1815-1820.
[9] Gibelli NE, Pinho-Apezzato ML, et al. Basiliximab-chimeric anti-IL-2-R monoclonal antibody in pediatric liver transplantation: comparative study. Transplant Proc,2004,36(4): 956-957.
[10] Suciu-Foca N, Cortesini R. Reviewing the mechanism of peripheral tolerance in clinical transplantation. Contrib Nephrol, 2005,146(1): 132-142.
[11] Neujahr D, Turka LA. Lymphocyte depletion as a barrier to immunological tolerance[J].Contrib Nephrol, 2005,146(1) : 65-72.
[12] Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest,2004,114(10) : 1398-1403.
[13] Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T cell derived lymphokines / cytokines.Proc Natl Acad Sci USA, 1989, 86:13332-13337
[14] Wiskocil R, Weiss A, Imboden J et al. Activation of a human T cell line: a two-stimulus requirement in the pretranslation events involved in the coordinate expression of interleukin-2 and r-interferon genes.J Immunol,1985,134:1599-1603
[15]Demirci G.Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28and CD154-independent rejection.J Immunol,2004,172:1691-1698.
[16]Kawai K,Shahinian A,Mak TW,et al.Skin allograft rejection in CD28-deficient mice.Transplantation,1996,61:352-355.
[17]Sugamttra K,Ishii N,Weinberg A.Therapeutic targeting of the effect T-cell co-stimulatory molecule OX40.Nature Reviews Immunology,2004,4:420-431.
[18]Chen AI,McAdam AJ,Buhlmamnn JE,et al.OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.Immtmity,1999,11:689-698.
[19]Murata K,Ishii N,Takano H,et al.Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.J Exp Med,2000,191:365-374.
[20]Zabairi S,Sanos SL,Hill S,et al.Immunotherapy with OX40L-Fc or anti-CTLA4enhances local tissue responses and killing of leishmania donovan.Eur J Immunol,2004,34:1433-1440.
[21]Kotani A,Ishikawa T,MatsumuraY,et al.Correlation of peripheral blood OX40~+(CD134~+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation[J].Blood,2001,98(10):3162-3164.
[22]Demirci G,Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28and CD154-independent rejection[J].J Immunol,2004,172(3):1691-1698.
[23]AB Adams,TR Jones,EA Heiss,et al.The CD134/CD134L pathway is critical in CD8-mediated costimulation blockade resistant rejection.Transplantation,2004,78(2):Supplement 1:181.
[24]Allison J.Curry,Jo Chikwe,Xin G.Smith,et al.OX40(CD134) Blockade Inhibits the Co-stimulatory Cascade and Promotes Heart Allograft Survival.Transplantation,2004,78(6):807-814.
[25]王光明,杨阳,李爱玲,等.CTLA4Ig和OX40Ig的表达及其生物学活性研究.中华微生物学和免疫学杂志,2005,25(5):383-387.
[26]王光明,孙涛,张元元,等.腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用.中华医学杂志,2005,85(48):3435-3439.
[27]Mosmann TR,Sad S.The expandind universe of T-cell subsets:Th1,Th2 and more[J].Immunol Today,1996,17:138-146.
[28]Neuberger J.Liver allograft rejection-current concepts on diagnosis and treatment [J].J Hepatol.1995,23(suppl 1):54.
[29]The European FK506 Multicentre Liver Study Group.Reduced incidence of acute,Refractory acute,And chronic rejection after liver transplantation with FK506-Based immunosuppression.Transplant Proc 1994;26:3260-3263.
[30]Neuhaus PJ.Optimised first-line FK506-Based protocols in liver transplantation;Experience from the university hospital rudolf virchow,Berlin.Transplant Proc 1994;26:3264-3266.
[1]Welch CS.A note on transplantation of the whole liver in dogs.Transplant Bull,1955.2:54.
[2]Cnon JA.Brief report.Transplant Bull,1956.3:7.
[3]Moore FD,Smith LL.Burnap TK,et al.One-stage homotransplantations of the liver following total hepatectomy in dogs.Transplant Bull,1959.6(1):103-110.
[4]Starzl TE,Marchioro TL,VonKaulla KN.et al.Homotransplansplantation of the liver in humans.Surg Gynecol Obstet,1963,117:659-676.
[5]Dawwas MF,Gimson AE,Lewsey JD,et al.Survival after liver transplantation in the United Kingdom and Ireland compared with the United States.Gut,2007,56(11):1606-1613.
[6]Perrella O,Sbreglia C,Arenga G,et al.Acute rejection after live transplantation:Is there a specific immunological pattern?Transplant Proc.2006;38(10):3594-3596.
[7]Trotter JF,Wachs M,Bak T,et al.Liver transplantation using sirolimus and minimal corticosteroids(3 day taper).Liver Transplant,2001,7(4):343-351.
[8] Barsher NR Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci, 2004, 9:411-420.
[9] Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs, 2002; 62(7): 995-1011.
[10] Vincenti F, Larsen C, Durrbach A. Costimulation blockade with belatacept in renal transplantation. N Engl Med, 2005, 353(8) : 770-781.
[11] changelian PS,Flanagan ME, Ball DJ,et al. Science, 2003. 302(5646): 875-878.
[1]Reiser H,Stadecker MJ.Co-stimulatory B7 molecules in the pathogenesis of infections and autoimmune disease[J].N Engl J Med,1996,335(18):1369-1377.
[2]Thompson CB,Lindsten T,Ledbetter JA,et al.CD28 activation pathway regulates the production of multiple T cell derived lymphokines/cytokines.Proc Natl Acad Sci USA,1989,86:13332-13337
[3]Wiskocil R,Weiss A,Imboden Jet al.Activation of a human T cell line:a two-stimulus requirement in the pretranslation events involved in the coordinate expression of interleukin-2 and r-interferon genes.J Immunol,1985,134:1599-1603
[4]Sugamttra K,Ishii N,Weinberg A.Therapeutic targeting of the effect T-cell co-stimulatory molecule OX40.Nature Reviews Immunology,2004,4:420-431.
[5]Yang Z,Rostami S,Koeberlein B,et al.Cardiac allografl tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig.Transplantation,1999,67(12):1517-1523.
[6]Azuma H,Chandraker A,Nadeau K,et al.Blockade of T-cell costimulation prevents development of experimental chronic renal allogaft rejection.Proc NatI Acad Sci USA,1996,93(22):12439-12444.
[7]Demirci G.Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28 and CD 154-independentrejection. J Immunol, 2004, 172:1691-1698.
[8] Kawai K, Shahinian A, Mak TW, et al. Skin allograft rejection in CD28-deficient mice. Transplantation, 1996, 61:352-355.
[9] Chen AI, McAdam AJ, Buhlmann JE, et al. OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immtmity, 1999,11:689-698.
[10] Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. JExpMed, 2000, 191:365-374.
[11] Zabairi S, Sanos SL, Hill S, et al. Immunotherapy with OX40L-Fc or anti-CTLA4 enhances local tissue responses and killing of leishmania donovan . Eur J Immunol,2004,34:1433-1440.
[12] Peterson DJ, Jefferis WA, Green JR, et al. Antigens of activated rat T lymphocytes including a molecule of 50, 000 Mr detected only on CD4 positive T blasts[J]. Mol Immunol, 1987, 24(12):1281-1290.
[13] Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes, a molecule related to nerve growth factor receptor[J].EMBO, 1990, 9(4):1063-1068.
[14] Calderhead DM, Buhlman JE, Eertwegh AJM, et al. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions [J]. J Immunol, 1993. 151(10):5261-5271.
[15] Latza U, Durkop H, Sehnittger S, et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen[J]. Eur J Immunol, 1994, 24(3):677-683.
[16] Miura S, Ohtani K, Numata N, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax[J]. Mol Cell Biol, 1991, 11(3): 1313-1325.
[17] Godfrey WR, Fagnoni FF, Harara MA, et al. Identification of a human OX40 ligand, a costimulator of CD4~+ T cells with homology to tumor necrosis factor[J]. J Exp Med, 1994,180(2):757-762.
[18] Flynn S, Toellner KM, Raykundalia C, et al. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 an d upregulates expression of the chemokine receptor, Blr-1[J]. J Exp Med, 1998, 188(2):297-304.
[19] Akiba H, Oshima H, Takeda K, et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. [J] . J Immunol, 1999, 162(12):7058-7066.
[20] Cheng B, Han S, Zhu Q, et al. Alternative pathways for the selection of antigen-specific peripheral T cells[J]. Nature, 1996, 384(6606):263-266.
[21] Weinberg AD, Vella AT, Croft M. OX40: life beyond the efector T cell stage[J]. semin Immunol, 1998, 10(6):471-480.
[22] Gramaglia I, Jember A, Pippig SD, et al. The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion[J]. the Journal of Immunology, 2000, 165(6):3043-3050.
[23] Gramaglia I, Weinberg AD, Lemon M, et al. Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses[J]. the Journal of Immunology, 1998, 161(12):6510-6517.
[24] Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-XI and Bcl-2 expression and is essential for long-term survival Of CD4 T cells[J]. Immunity, 2001,15(3):445-455.
[25] Weatherill AR, Maxwell JR. Takahashi C, et al. OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo[J]. Cell Immunol, 2001,209(1):63-75.
[26] Rogers PR, Song J, Gramaglia I, et al. OX40 promotos Bcl.XI and Bcl.2 expression and is essential for long-term survival of CD4 T cells[J]. Immunity, 2001,15(3):445-455.
[27] De S T, Smith J, Baum P, et al. Ox40 Costimulation Enhances the Development of T Cell Responses Induced by Dendritic Cell In Vivo[J]. the Journal of Immunology, 2002, 168(2):661-670.
[28] Weinberg AD, Wallin JJ, Jones RE, et al. Target organ specific upregulation of the MRC OX40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis [J]. J Immunol , 1994 , 152:4712-4721.
[29] Vetto JT, Lum S, Morris A, et al. Presence of the T cell activation marker 0X40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head neck cancers[J]. Am J Surg, 1997, 174(3):258-265.
[30] Weinberg AD, Sullivan TJ, Lemon M, et al. Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis [J]. Nature Med, 1996, 2(2):183-189.
[31] Weinberg AD. Antibodies to OX40 (CD 134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease[J]. Mol Med Today, 1998,4(2):76-83.
[32] Tittle TV, Weinberg AD, Steinkeler CN, et al. Expression of the T cell activation antigen, OX40, identifies alloreactive T cells in acute Graft-Versus-Host Disease[J]. Blood, 1997, 89(12):4652-4658.
[33] Patrick H. Still a long way to go before immune tolerance. Transplantation, 2002, 73(1 Suppl): S43-44.
[34] Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunology, 2004, 172: 1691-1698
[35] Peter L. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper(Th)1 and Th2 cells. J Exp Med, 2000, 191:201-205
[36] Prell R A, Evans D E, Thalhofer C, et al. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. Journal Immunology, 2003, 171:5997-6005
[37] Curry A J, Chikwe J, Smith X G, et al. OX40(CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft Survival. Transplantation, 2004, 78:807-814
[38] Kalinsk P,Hikens CMH, Wiereng EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. [J]. Immunol Today, 1999, 20(11):561-566.
[39] Tanaka H, Demeure CE, Rubio M, et al. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. [J]. J Exp Med, 2000, 192(3):405-412.
[40] Ohshima Y, Yang LP, Uchivama T, et al. OX40 costimulation enhances interleukin-4(IL-4) expresion at priming and promotes the differentiation of naive human CD4(+)T cells into high IL- 4 producing effectors[J]. Blood, 1998,92(9):3338-3345.
[41] Delespesse G, Ohshima Y, Yang LP, et al. OX40-Mediated cosignal enhances the maturation of naive human CD4+ T cells into high IL-4-producing effectors.[J]. Int Arch Allergy Immunol, 1999, 118(2-4):384-386.
[42] AkibaH, MiyahiraY, AtsutaM, et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis[J]. J Exp Med, 2000,191(2):375-380.
[43] Lane P. Role of OX40 Signals in Coordinating CD4 T Cell Selection, Migration, and Cytokine Differentiation in T Helper(Th)1 and Th2 Cells[J]. J Exp Med. 2000, 191(2):201-205.
[44] Walker LS, Gulbranson-Judge A, Flynn S, et al. Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. [J]. Immunol Today, 2000, 21(7):333-337.
[45] Brocker T, Gulbranson-Judge A, Flynn S, et al. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. [J]. Eur J Immunol, 1999, 29(5):1610-1616.
[46] Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance [J]. Nat Med, 2001, 7(8): 907-912.
[47] Rogers PR, song j, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. [J]. Immunity. 2001, 15(3):445-455.
[48] Chen AI, McAdam AJ, Buhlmann JE, et al. OX40-ligand has a critical costimulatory role in dendritic cell: T cell interactions[J]. Immunity, 1999, 11(6):689-698.
[49] Takaori-Kondo A, Hori T, Fukunaga K, et al. Both amino-and carboxyl-terminal domains Of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling[J]. Biochem Biophys Res Commun. 2000, 272(3):856-863.
[50] Hong Ye, Hao Wu. Thermodynaniic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry[J]. Proc Natl Acad Sci USA, 2000, 97(16):8961-8966.
[51] Pankow R, Durkop H, Latza U, et al. The HTLV.1 tax protein transcriptionally modulates OX40 antigen expression[J]. J Immunol, 2000, 165(l):263-270.
[52] Prell RA, Evans DE, Thalhofer C, et al. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent[J] . J Immunol , 2003 , 171(11):5997-6005.
[53] Song J, Salek-Ardakani S, Rogers PR, et al. The costimulation-regulated duration ofPKB activation controls T cell longevity[J]. Nat Immunol, 2004, 5(2):150-158.
[54] Weinberg AD. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines [J]. Trends Immunol, 2002, 23(2):102-109.
[55] Muy-Rivera M, Lemon M, Funatake C, et al. Enhancement of antitumor immunity by engaging the OX40 receptor(CD 134) in vivo[J]. AACR Meeting / New Orleans Abstract, 1998,3610:193.
[56] Smyth MJ, Godfrey DI, Trapani IA. A fresh look at tumor immunosurveillance and immunotherapy. [J]. Nat Immunol, 2001, 2(4):293-299.
[57] Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.[J]. Trends Immunol, 2001, 22(5):269-276
[58] Nohara C, Akiba H, Nakajima A, et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. [J]. J Immunol, 2001, 166(3):2108-2115.
[59] Saijo SJ, Asano M, Horai R, et al. Suppression of autoimmune arthritis in interleukin-1 -deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. [J]. Arthritis Rheum, 2002, 46(2):533-534.
[60] Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein [J]. J Immunol, 1999, 162(l):486-493.
[61] Imura A, Hori T, ImadaK. et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells [J]. J Exp Med, 1996, 183(5):2185-2195.
[62] Tian LN, Guo WH, Yuan ZW, et al. Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft [J]. Transplantation, 2002, 74(1): 133-138.
[63] Kotani A, Ishikawa T, Matsumura Y, et al. Correlation of peripheral blood OX40~+(CD134~+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation[J]. Blood, 2001, 98(10):3162-3164.
[64] Demirci G, AmanullahF, Kewalaramani R, etal. Critical role of OX40 in CD28 and CD154-independentrejection[J]. J Immunol, 2004, 172(3):1691-1698.
[65] AB Adams, TR Jones, EA Heiss, et al. The CD134/CD134L pathway is critical in CD8-mediated costimulation blockade resistant rejection. Transplantation, 2004, 78(2):Supplement 1:181.
[66]Allison J.Curry,Jo Chikwe,Xin G.Smith,et al.OX40(CD134) Blockade Inhibits the Co-stimulatory Cascade and Promotes Heart Allograft Survival.Transplantation,2004,78(6):807-814.
[67]王光明,杨阳,李爱玲,等.CTLA4Ig和OX40Ig的表达及其生物学活性研究.中华微生物学和免疫学杂志,2005,25(5):383-387.
[68]王光明,孙涛,张元元,等.腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用.中华医学杂志,2005,85(48):3435-3439.
[2]Perrella O,Sbreglia C,Arenga G,et al.Acute rejection after live transplantation:Is there a specific immunological pattern?Transplant Proc,2006,38(10):3594-3596.
[3]Michel F,Attal Bonnefoy G,Mangino G,et al.CD28 as a molecular amplifier extending TCR ligation and signaling capaling capabilities.Immunity,2001,15(6):935-945.
[4]Sugamttra K,Ishii N,Weinberg A.Therapeutic targeting of the effect T-cell co-stimulatory molecule OX40.Nature Reviews Immunology,2004,4:420-431.
[5]Chen AI,McAdam AJ,Buhlmann JE,et al.OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.Immtmity,1999,11:689-698.
[6]Murata K,Ishii N,Takano H,et al.Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.J Exp Med,2000,191:365-374.
[7]Zabairi S,Sanos SL,Hill S,et al.Immunotherapy with OX40L-Fc or anti-CTLA4enhances local tissue responses and killing of leishmania donovan.Eur J Immunol,2004,34:1433-1440.
[8]Weinberg AD.OX40:targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines[J].Trends Immunol,2002,23(2):102-109.
[9]Kotani A,Ishikawa T,MatsumuraY,et al.Correlation of peripheral blood OX40~+(CD134~+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation[J].Blood,2001,98(10):3162-3164.
[10]Demirci G,Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28and CD154-independent rejection[J].J Immnunol,2004,172(3):1691-1698.
[11]AB Adams,TR Jones,EA Heiss,et al.The CD134/CD134L pathway is critical in CD8-mediated costimulation blockade resistant rejection.Transplantation,2004,78(2):Supplement 1:181.
[12]Allison J.Curry,Jo Chikwe,Xin G.Smith,et al.OX40(CD134) Blockade Inhibits the Co-stimulatory Cascade and Promotes Heart Allograft Survival.Transplantation,2004,78(6):807-814.
[13]王光明,杨阳,李爱玲,等.CTLA4Ig和OX40Ig的表达及其生物学活性研究.中华微生物学和免疫学杂志,2005,25(5):383-387.
[14]王光明,孙涛,张元元,等.腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用.中华医学杂志,2005,85(48):3435-3439.
[1]余斌,秦磊,钱海鑫.大鼠肝移植的麻醉.苏州大学学报(医学版),2005,25(2):245-247.
[2]彭勇,龚建平,严律南.大鼠原位肝移植模型制作过程中麻醉方法的选择.中国普通外科杂志,2003,12:673-676.
[3]Lee S,Charters C,Chandler J,Orloff M.A technique for orthotopic liver transplantation in the rat,Transplantation,1973,16:664-669.
[4]Lee S,Chaners C,Orloff M.Simplified technique for Orthotopic liver transplantation in the rat.Am J Surg,1975,130:38-40.
[5]Kamada N,Calne RY.Orthotopic liver transplantation in the rat.Transplantation,1979,28:47-50.
[6]Zimmerman FA,Butcher GW,Davies HS,et al.Techniques for orthotopic liver transplantation in the rat and some studies of the immunologic responses to fully allogenetic liver grafts.Transplant Proc,1979,11:571-574.
[7]Kamada N,Calne R,A surgical experience with five hundred thirty liver transplantation in the rat.Surgery,1983,93:64-69.
[8]Miyata M,Fisher J,Fuhs M.et al A simple method for orthotopic liver transplantation in the rat.Transplantation 1980;30:335-338.
[9]Hasuike Y,Monden M,Valdivia LA,et al A simple method for orthotopic liver transplantation with arterial reconstruction in rats.Transplantation 1988,45:830-832.
[10]Steffen R,Ferguson DM,Krom RAF A new method orthotopic rat liver transplantation with arterial cuff anastomosis to the recipient common hepatic artery. Transplantation 1989,48: 166-168.
[11] Howden B, Jabronski P,Grossman H, et al The importance of the hepatic artery in rat liver transplantation. Transplantation 1989,47: 428-431.
[12] Chaland P.Braillon A, Gaudin C, et al Orthotopic liver transplantation with hepatic artery Transplantation 1990, 49: 675-679.
[13] Liu L, Freise CE, Ferell L, et al A modified vascular "sleeve" anastomoses for rearterialization in orthotopic liver transplantation in the rats Transplantation 1992, 54:179-180.
[14] Knoop M, Bachmann S, Keck H, et al Experience with cuff rearterialization in 600 Orthotopic liver grafts in the rat. Am J Surg 1994,167: 360-363.
[1]Banff schema for grading liver allograft rejection:an international consensus document.Hepatology,1997,25(3):658-663.
[2]Lee S,Charters AC,Chandler JG,et al.A technique for orthotopic liver transplantation in the rat[J].Transplantation,1973,16:664-669.
[3]Kamada N,Calne RY.Orthotopic liver transplantation in the rat.Techniques using cuff for portal vein anastomosis and biliary drainage[J].Transplantation,1979,28(1):47-49.
[4]Kamada N,Calne RY.A surgical experiment with five hundred thirty liver transplants in the rat[J].Surgery,1983,93(1):64-69.
[5]Zimmermann FA,et al.The fate of Orthotopic liver allografts in different rat strain combination[J]Transp Proc,1983,15:1272.
[6]邵义祥 医学实验动物学.东南大学出版社,2003:12。
[7]龚非力.医学免疫学.北京:科学出版社.2003,101。
[8]Mosmann TR,Sad S.The expandind universe of T-cell subsets:Th1,Th2 and more[J].Immunol Today,1996,17:138-146.
[9]Neuberger J.Liver allograft rejection-current concepts on diagnosis and treatment[J].J Hepatol.1995,23(suppl 1):54-61.
[10]许赤,黄洁夫,陈规划,等。大鼠肝移植术后早期急性排斥反应与细胞因子基因表达的关系 [J]。肝胆外科杂志,2000,8(3):229-230。
[11]Boecolo P,et al.The immune response of women with prolonged exposure to electromagnetic fields produced by radiotelevision broadcasting stations.Int J Immunopathol Pharmacol.2006,19(4):43.
[12]Furukawa Y,Becker G,Stinn L,et al.Interleukin-10 augments allograft arterial disease:paradoxical effects of IL-10 in vivo[J].Am J Patnol,1999,155:1929-1939.
[13]DM Plaza,D Fernandez,M Builes,et al.Cytokine gene polymorphisms in heart transplantation:association of low IL-10 production genotype with quilty effect[J].J Heart Lung Transplant,2003,22(8):851-856.
[14]邹晓明,杨维良,姜学海,等。RhIL-10在大鼠肝移植再灌注损伤和急性排斥反应中的作用[J]。中华普通外科杂志,2002,17(2):96-98。
[15]Qin L,Ding Y,Tahara H,et al.Viral IL-10-induced immunosuppression requires Th2 cytokines and impairs APC function within the allograft[J].Immunol.2001,166:2385-2393.
[16]芮晓辉,蔡端,张群华,等。TNF-α和IL-10在非协调性异种肝移植中的作用探讨[J]。中华肝胆外科杂志,2002,8(11):680-682。
[17]王光明,孙涛,张元元,等。腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用[J]。中华医学杂志,2005,85(48):3435-3439。
[18]Qian S,Lu L,Fu F,et al.Apoptosis within spontaneously accepted mouse liver allografts[J].J Immunol,1997,158:4654-4661.
[19]Shintaku S,Ohdan H,et al.Expression of bcl-2 homologue mRNAs in rat liver allograft:rejection -induced cell apoptosis is associated with up-regulation of bax and bcl-xs expression[J].Transplant Int,1998,11(Suppl):284-288.
[20]Tannapfel A,Kohlhaw K,Ebelt J,et al.Apoptosis and the expression of Fas and Fas ligand(FasL)antigen in rejection and reinfection in liver allograft specimens[J].Transplantation,1999,67(7):1079-1083.
[21]刘玉兰,刘峰,孙君泓。Fas/FasL表达和细胞凋亡在大鼠同种异体肝移植免疫中的作用[J]。中华普通外科杂志,2003,18(2):99-101。
[22]Maciejewski J,Selleri C,Anderson S,et al.Fas antigen expression on CD34+human marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro[J].Blood,1995,85(11):3183-3190.
[23]Xu X,Fu xy,P late J,et al.IFN-gamma induce cell growth inhibition by Fas-mediated apoptosis:requirement of STAT1 protein for up-regulation of Fas and FasL expression[J].Cancer Res,1998,58(13):2832-2837.
[1]Jeffrey M.Isner,Peter R.Vale,James F.Symes,et al.Assessment of risks associated with cardiovascular gene therapy in human subjects.Circ Res.2001,89:389-400.
[2]Nielsen LL,Gurnani M,Syed L,et al.Recombinant E1-deleted adenovirus mediated gene therapy for cancer efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Human gene therapy,1998,9:681-694.
[3]Kremer EJ,Perricaudet M.Adenovirus and adenovirus associated virus mediated gene transfer.Brit Med Bull,1995,51:31-44.
[4]French BA,Mazur W,Geske RS,et al.Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors.Circulation,1994,90:革者2414-2424.
[5]F.奥斯伯 等著,颜子颖 等译.精编分子生物学实验指南.北京:科学技术出版所,1998:276.
[1]Melillo G,Scoccianti M,Lovesdi I,et al.Gene therapy for collateral vessel de2velopment.Cardiovascular Res,1997,35(2):480-489.
[2]Yl(a|¨)-Herttuala S.Vascular gene tranfer.Curr Opin Lipidol,1997,8:72-76.
[3]Jeffrey M.Isner,Peter R.Vale,James F.Symes,et al.Assessment of risks associated with cardiovascular gene therapy in human subjects.Circ Res.2001,89:389-400.
[4]Nielsen LL,Gurnani M,Syed L,et al.Recombinant E1-deleted adenovirus mediated gene therapy for cancer efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.Human gene therapy,1998,9:681-694.
[5]Kremer EJ,Perricaudet M.Adenovirus and adenovirus associated virus mediated gene transfer.Brit Med Bull,1995,51:31-44.
[6]Hong SS,Karayan L,Toumier J,et al.Adenovirus type 5fiber knob binds to MHC cIass Ⅰα2 domain at the surface of human epithelial and B lymphoblastoid cells.EMBOJ,1997,16:2291-2306.
[7]Kass-eisler A,Falck-pedersen E,Alvira M,et al.Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo.Proc Nati Acad Sci USA,1993,90:11498-11502.
[1]Dawwas MF,Gimson AE,Lewsey JD,et al.Survival after liver transplantation in the United Kingdom and Ireland compared with the United States.Gut,2007,56(11):1606-1613.
[2] PeiTella O,Sbreglia C,Arenga G,et al.Acute rejection after live transplantation: Is there a specific immunological pattern?Transplant Proc.2006; 38(10): 3594-3596.
[3] Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids(3 day taper). Liver Transplant, 2001, 7(4): 343-351.
[4] Barsher NR Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci, 2004, 9:411-420.
[5] Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs, 2002; 62(7): 995-1011.
[6] Vincenti F, Larsen C, Durrbach A. Costimulation blockade with belatacept in renal transplantation. N Engl Med, 2005, 353(8): 770-781.
[7] changelian PS,Flanagan ME, Ball DJ,et al. Science, 2003. 302(5646): 875-878.
[8] Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation,2004,77(12): 1815-1820.
[9] Gibelli NE, Pinho-Apezzato ML, et al. Basiliximab-chimeric anti-IL-2-R monoclonal antibody in pediatric liver transplantation: comparative study. Transplant Proc,2004,36(4): 956-957.
[10] Suciu-Foca N, Cortesini R. Reviewing the mechanism of peripheral tolerance in clinical transplantation. Contrib Nephrol, 2005,146(1): 132-142.
[11] Neujahr D, Turka LA. Lymphocyte depletion as a barrier to immunological tolerance[J].Contrib Nephrol, 2005,146(1) : 65-72.
[12] Walsh PT, Taylor DK, Turka LA. Tregs and transplantation tolerance. J Clin Invest,2004,114(10) : 1398-1403.
[13] Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T cell derived lymphokines / cytokines.Proc Natl Acad Sci USA, 1989, 86:13332-13337
[14] Wiskocil R, Weiss A, Imboden J et al. Activation of a human T cell line: a two-stimulus requirement in the pretranslation events involved in the coordinate expression of interleukin-2 and r-interferon genes.J Immunol,1985,134:1599-1603
[15]Demirci G.Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28and CD154-independent rejection.J Immunol,2004,172:1691-1698.
[16]Kawai K,Shahinian A,Mak TW,et al.Skin allograft rejection in CD28-deficient mice.Transplantation,1996,61:352-355.
[17]Sugamttra K,Ishii N,Weinberg A.Therapeutic targeting of the effect T-cell co-stimulatory molecule OX40.Nature Reviews Immunology,2004,4:420-431.
[18]Chen AI,McAdam AJ,Buhlmamnn JE,et al.OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.Immtmity,1999,11:689-698.
[19]Murata K,Ishii N,Takano H,et al.Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.J Exp Med,2000,191:365-374.
[20]Zabairi S,Sanos SL,Hill S,et al.Immunotherapy with OX40L-Fc or anti-CTLA4enhances local tissue responses and killing of leishmania donovan.Eur J Immunol,2004,34:1433-1440.
[21]Kotani A,Ishikawa T,MatsumuraY,et al.Correlation of peripheral blood OX40~+(CD134~+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation[J].Blood,2001,98(10):3162-3164.
[22]Demirci G,Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28and CD154-independent rejection[J].J Immunol,2004,172(3):1691-1698.
[23]AB Adams,TR Jones,EA Heiss,et al.The CD134/CD134L pathway is critical in CD8-mediated costimulation blockade resistant rejection.Transplantation,2004,78(2):Supplement 1:181.
[24]Allison J.Curry,Jo Chikwe,Xin G.Smith,et al.OX40(CD134) Blockade Inhibits the Co-stimulatory Cascade and Promotes Heart Allograft Survival.Transplantation,2004,78(6):807-814.
[25]王光明,杨阳,李爱玲,等.CTLA4Ig和OX40Ig的表达及其生物学活性研究.中华微生物学和免疫学杂志,2005,25(5):383-387.
[26]王光明,孙涛,张元元,等.腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用.中华医学杂志,2005,85(48):3435-3439.
[27]Mosmann TR,Sad S.The expandind universe of T-cell subsets:Th1,Th2 and more[J].Immunol Today,1996,17:138-146.
[28]Neuberger J.Liver allograft rejection-current concepts on diagnosis and treatment [J].J Hepatol.1995,23(suppl 1):54.
[29]The European FK506 Multicentre Liver Study Group.Reduced incidence of acute,Refractory acute,And chronic rejection after liver transplantation with FK506-Based immunosuppression.Transplant Proc 1994;26:3260-3263.
[30]Neuhaus PJ.Optimised first-line FK506-Based protocols in liver transplantation;Experience from the university hospital rudolf virchow,Berlin.Transplant Proc 1994;26:3264-3266.
[1]Welch CS.A note on transplantation of the whole liver in dogs.Transplant Bull,1955.2:54.
[2]Cnon JA.Brief report.Transplant Bull,1956.3:7.
[3]Moore FD,Smith LL.Burnap TK,et al.One-stage homotransplantations of the liver following total hepatectomy in dogs.Transplant Bull,1959.6(1):103-110.
[4]Starzl TE,Marchioro TL,VonKaulla KN.et al.Homotransplansplantation of the liver in humans.Surg Gynecol Obstet,1963,117:659-676.
[5]Dawwas MF,Gimson AE,Lewsey JD,et al.Survival after liver transplantation in the United Kingdom and Ireland compared with the United States.Gut,2007,56(11):1606-1613.
[6]Perrella O,Sbreglia C,Arenga G,et al.Acute rejection after live transplantation:Is there a specific immunological pattern?Transplant Proc.2006;38(10):3594-3596.
[7]Trotter JF,Wachs M,Bak T,et al.Liver transplantation using sirolimus and minimal corticosteroids(3 day taper).Liver Transplant,2001,7(4):343-351.
[8] Barsher NR Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci, 2004, 9:411-420.
[9] Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs, 2002; 62(7): 995-1011.
[10] Vincenti F, Larsen C, Durrbach A. Costimulation blockade with belatacept in renal transplantation. N Engl Med, 2005, 353(8) : 770-781.
[11] changelian PS,Flanagan ME, Ball DJ,et al. Science, 2003. 302(5646): 875-878.
[1]Reiser H,Stadecker MJ.Co-stimulatory B7 molecules in the pathogenesis of infections and autoimmune disease[J].N Engl J Med,1996,335(18):1369-1377.
[2]Thompson CB,Lindsten T,Ledbetter JA,et al.CD28 activation pathway regulates the production of multiple T cell derived lymphokines/cytokines.Proc Natl Acad Sci USA,1989,86:13332-13337
[3]Wiskocil R,Weiss A,Imboden Jet al.Activation of a human T cell line:a two-stimulus requirement in the pretranslation events involved in the coordinate expression of interleukin-2 and r-interferon genes.J Immunol,1985,134:1599-1603
[4]Sugamttra K,Ishii N,Weinberg A.Therapeutic targeting of the effect T-cell co-stimulatory molecule OX40.Nature Reviews Immunology,2004,4:420-431.
[5]Yang Z,Rostami S,Koeberlein B,et al.Cardiac allografl tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig.Transplantation,1999,67(12):1517-1523.
[6]Azuma H,Chandraker A,Nadeau K,et al.Blockade of T-cell costimulation prevents development of experimental chronic renal allogaft rejection.Proc NatI Acad Sci USA,1996,93(22):12439-12444.
[7]Demirci G.Amanullah F,Kewalaramani R,et al.Critical role of OX40 in CD28 and CD 154-independentrejection. J Immunol, 2004, 172:1691-1698.
[8] Kawai K, Shahinian A, Mak TW, et al. Skin allograft rejection in CD28-deficient mice. Transplantation, 1996, 61:352-355.
[9] Chen AI, McAdam AJ, Buhlmann JE, et al. OX40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immtmity, 1999,11:689-698.
[10] Murata K, Ishii N, Takano H, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. JExpMed, 2000, 191:365-374.
[11] Zabairi S, Sanos SL, Hill S, et al. Immunotherapy with OX40L-Fc or anti-CTLA4 enhances local tissue responses and killing of leishmania donovan . Eur J Immunol,2004,34:1433-1440.
[12] Peterson DJ, Jefferis WA, Green JR, et al. Antigens of activated rat T lymphocytes including a molecule of 50, 000 Mr detected only on CD4 positive T blasts[J]. Mol Immunol, 1987, 24(12):1281-1290.
[13] Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes, a molecule related to nerve growth factor receptor[J].EMBO, 1990, 9(4):1063-1068.
[14] Calderhead DM, Buhlman JE, Eertwegh AJM, et al. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions [J]. J Immunol, 1993. 151(10):5261-5271.
[15] Latza U, Durkop H, Sehnittger S, et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen[J]. Eur J Immunol, 1994, 24(3):677-683.
[16] Miura S, Ohtani K, Numata N, et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax[J]. Mol Cell Biol, 1991, 11(3): 1313-1325.
[17] Godfrey WR, Fagnoni FF, Harara MA, et al. Identification of a human OX40 ligand, a costimulator of CD4~+ T cells with homology to tumor necrosis factor[J]. J Exp Med, 1994,180(2):757-762.
[18] Flynn S, Toellner KM, Raykundalia C, et al. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 an d upregulates expression of the chemokine receptor, Blr-1[J]. J Exp Med, 1998, 188(2):297-304.
[19] Akiba H, Oshima H, Takeda K, et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. [J] . J Immunol, 1999, 162(12):7058-7066.
[20] Cheng B, Han S, Zhu Q, et al. Alternative pathways for the selection of antigen-specific peripheral T cells[J]. Nature, 1996, 384(6606):263-266.
[21] Weinberg AD, Vella AT, Croft M. OX40: life beyond the efector T cell stage[J]. semin Immunol, 1998, 10(6):471-480.
[22] Gramaglia I, Jember A, Pippig SD, et al. The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion[J]. the Journal of Immunology, 2000, 165(6):3043-3050.
[23] Gramaglia I, Weinberg AD, Lemon M, et al. Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses[J]. the Journal of Immunology, 1998, 161(12):6510-6517.
[24] Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-XI and Bcl-2 expression and is essential for long-term survival Of CD4 T cells[J]. Immunity, 2001,15(3):445-455.
[25] Weatherill AR, Maxwell JR. Takahashi C, et al. OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo[J]. Cell Immunol, 2001,209(1):63-75.
[26] Rogers PR, Song J, Gramaglia I, et al. OX40 promotos Bcl.XI and Bcl.2 expression and is essential for long-term survival of CD4 T cells[J]. Immunity, 2001,15(3):445-455.
[27] De S T, Smith J, Baum P, et al. Ox40 Costimulation Enhances the Development of T Cell Responses Induced by Dendritic Cell In Vivo[J]. the Journal of Immunology, 2002, 168(2):661-670.
[28] Weinberg AD, Wallin JJ, Jones RE, et al. Target organ specific upregulation of the MRC OX40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis [J]. J Immunol , 1994 , 152:4712-4721.
[29] Vetto JT, Lum S, Morris A, et al. Presence of the T cell activation marker 0X40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head neck cancers[J]. Am J Surg, 1997, 174(3):258-265.
[30] Weinberg AD, Sullivan TJ, Lemon M, et al. Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis [J]. Nature Med, 1996, 2(2):183-189.
[31] Weinberg AD. Antibodies to OX40 (CD 134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease[J]. Mol Med Today, 1998,4(2):76-83.
[32] Tittle TV, Weinberg AD, Steinkeler CN, et al. Expression of the T cell activation antigen, OX40, identifies alloreactive T cells in acute Graft-Versus-Host Disease[J]. Blood, 1997, 89(12):4652-4658.
[33] Patrick H. Still a long way to go before immune tolerance. Transplantation, 2002, 73(1 Suppl): S43-44.
[34] Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunology, 2004, 172: 1691-1698
[35] Peter L. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper(Th)1 and Th2 cells. J Exp Med, 2000, 191:201-205
[36] Prell R A, Evans D E, Thalhofer C, et al. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. Journal Immunology, 2003, 171:5997-6005
[37] Curry A J, Chikwe J, Smith X G, et al. OX40(CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft Survival. Transplantation, 2004, 78:807-814
[38] Kalinsk P,Hikens CMH, Wiereng EA, et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. [J]. Immunol Today, 1999, 20(11):561-566.
[39] Tanaka H, Demeure CE, Rubio M, et al. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. [J]. J Exp Med, 2000, 192(3):405-412.
[40] Ohshima Y, Yang LP, Uchivama T, et al. OX40 costimulation enhances interleukin-4(IL-4) expresion at priming and promotes the differentiation of naive human CD4(+)T cells into high IL- 4 producing effectors[J]. Blood, 1998,92(9):3338-3345.
[41] Delespesse G, Ohshima Y, Yang LP, et al. OX40-Mediated cosignal enhances the maturation of naive human CD4+ T cells into high IL-4-producing effectors.[J]. Int Arch Allergy Immunol, 1999, 118(2-4):384-386.
[42] AkibaH, MiyahiraY, AtsutaM, et al. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis[J]. J Exp Med, 2000,191(2):375-380.
[43] Lane P. Role of OX40 Signals in Coordinating CD4 T Cell Selection, Migration, and Cytokine Differentiation in T Helper(Th)1 and Th2 Cells[J]. J Exp Med. 2000, 191(2):201-205.
[44] Walker LS, Gulbranson-Judge A, Flynn S, et al. Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. [J]. Immunol Today, 2000, 21(7):333-337.
[45] Brocker T, Gulbranson-Judge A, Flynn S, et al. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. [J]. Eur J Immunol, 1999, 29(5):1610-1616.
[46] Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance [J]. Nat Med, 2001, 7(8): 907-912.
[47] Rogers PR, song j, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. [J]. Immunity. 2001, 15(3):445-455.
[48] Chen AI, McAdam AJ, Buhlmann JE, et al. OX40-ligand has a critical costimulatory role in dendritic cell: T cell interactions[J]. Immunity, 1999, 11(6):689-698.
[49] Takaori-Kondo A, Hori T, Fukunaga K, et al. Both amino-and carboxyl-terminal domains Of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling[J]. Biochem Biophys Res Commun. 2000, 272(3):856-863.
[50] Hong Ye, Hao Wu. Thermodynaniic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry[J]. Proc Natl Acad Sci USA, 2000, 97(16):8961-8966.
[51] Pankow R, Durkop H, Latza U, et al. The HTLV.1 tax protein transcriptionally modulates OX40 antigen expression[J]. J Immunol, 2000, 165(l):263-270.
[52] Prell RA, Evans DE, Thalhofer C, et al. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent[J] . J Immunol , 2003 , 171(11):5997-6005.
[53] Song J, Salek-Ardakani S, Rogers PR, et al. The costimulation-regulated duration ofPKB activation controls T cell longevity[J]. Nat Immunol, 2004, 5(2):150-158.
[54] Weinberg AD. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines [J]. Trends Immunol, 2002, 23(2):102-109.
[55] Muy-Rivera M, Lemon M, Funatake C, et al. Enhancement of antitumor immunity by engaging the OX40 receptor(CD 134) in vivo[J]. AACR Meeting / New Orleans Abstract, 1998,3610:193.
[56] Smyth MJ, Godfrey DI, Trapani IA. A fresh look at tumor immunosurveillance and immunotherapy. [J]. Nat Immunol, 2001, 2(4):293-299.
[57] Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.[J]. Trends Immunol, 2001, 22(5):269-276
[58] Nohara C, Akiba H, Nakajima A, et al. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. [J]. J Immunol, 2001, 166(3):2108-2115.
[59] Saijo SJ, Asano M, Horai R, et al. Suppression of autoimmune arthritis in interleukin-1 -deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. [J]. Arthritis Rheum, 2002, 46(2):533-534.
[60] Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein [J]. J Immunol, 1999, 162(l):486-493.
[61] Imura A, Hori T, ImadaK. et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells [J]. J Exp Med, 1996, 183(5):2185-2195.
[62] Tian LN, Guo WH, Yuan ZW, et al. Association of the CD134/CD134L costimulatory pathway with acute rejection of small bowel allograft [J]. Transplantation, 2002, 74(1): 133-138.
[63] Kotani A, Ishikawa T, Matsumura Y, et al. Correlation of peripheral blood OX40~+(CD134~+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation[J]. Blood, 2001, 98(10):3162-3164.
[64] Demirci G, AmanullahF, Kewalaramani R, etal. Critical role of OX40 in CD28 and CD154-independentrejection[J]. J Immunol, 2004, 172(3):1691-1698.
[65] AB Adams, TR Jones, EA Heiss, et al. The CD134/CD134L pathway is critical in CD8-mediated costimulation blockade resistant rejection. Transplantation, 2004, 78(2):Supplement 1:181.
[66]Allison J.Curry,Jo Chikwe,Xin G.Smith,et al.OX40(CD134) Blockade Inhibits the Co-stimulatory Cascade and Promotes Heart Allograft Survival.Transplantation,2004,78(6):807-814.
[67]王光明,杨阳,李爱玲,等.CTLA4Ig和OX40Ig的表达及其生物学活性研究.中华微生物学和免疫学杂志,2005,25(5):383-387.
[68]王光明,孙涛,张元元,等.腺病毒介导的CTLA4Ig和OX40Ig基因转移诱导大鼠心脏移植物长期存活的作用.中华医学杂志,2005,85(48):3435-3439.